Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review

Archives of Internal Medicine

Volumn 170, Issue 19, 2010, Pages 1710-1716

  Iorio, Alfonso ^a,b   Kearon, Clive ^b   Filippucci, Esmeralda ^c   Marcucci, Maura ^a   Macura, Ana ^a   Pengo, Vittorio ^d   Siragusa, Sergio ^e   Palareti, Gualtiero ^f  

^a UNIVERSITY OF PERUGIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c Hospital of Foligno   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; FOLLOW UP; HUMAN; LUNG EMBOLISM; METHODOLOGY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGERY; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM; INCIDENCE; PROCEDURES; PROGNOSIS; RECURRENT DISEASE;

HUMANS; INCIDENCE; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 78049252755     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.367     Document Type: Review

References (22)

1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):454S-545S.
2. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340(8824):873-876.
3. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74(2):606-611.
4. Schulman S, Rhedin AS, Lindmarker P, et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332(25):1661-1665.
5. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769-774.
6. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523-526.
7. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6(1):5-30. (Pubitemid 20287159)
8. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50. doi:10.1186/1471-2288-6-50.
9. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: a randomized study. Acta Med Scand. 1985;217(5):547-552.
10. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87(1):7-12.
11. Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955-960.
12. Kearon C, Ginsberg JS, Anderson DR, et al; SO-FAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2(5):743-749.
13. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25.
14. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-2361.
15. García-Fuster MJ, Forner MJ, Fernández C, Gil J, Vaya A, Maldonado L. Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol Haemost Thromb. 2005;34(1):6-12.
16. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
17. Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Anticoagulation quality and the risk of recurrence of venous thromboembolism. Thromb Haemost. 2007;98(5):1148-1150. (Pubitemid 350091149)
18. Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost. 2008;6(4):577-582.
19. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-426.
20. Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481-490, W94.
21. Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112(3):511-515.
22. Snow V, Qaseem A, Barry P, et al; American College of Physicians; American Academy of Family Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146(3):204-210.